Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Grant Dorsey, MD, PhD
- Phone Number: 628-206-4680
- Email: grant.dorsey@ucsf.edu
Study Contact Backup
- Name: Abel Kakuru, MBChB, PhD
- Phone Number: +256 (0) 312 281 479
- Email: akakuru@idrc-uganda.org
Study Locations
-
-
Busia
-
Masafu, Busia, Uganda
- Infectious Diseases Research Collaboration Clinic - Masafu Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Viable singleton pregnancy confirmed by ultrasound
- Estimated gestational age between 12-20 weeks
- Confirmed to be HIV- uninfected by rapid test
- 16 years of age or older
- Residency within Busia District of Uganda
- Provision of informed consent
- Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol
- Willing to deliver in the hospital
Exclusion Criteria:
- History of serious adverse event to SP or DP
- Active medical problem requiring inpatient evaluation at the time of screening
- Intention of moving outside of Busia District Uganda
- Chronic medical condition requiring frequent medical attention
- Prior chemopreventive therapy or any other antimalarial therapy during this pregnancy
- Early or active labor (documented by cervical change with uterine contractions)
- Multiple pregnancies (i.e. twins/triplets)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: SP + DP placebo every 4 weeks
|
SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda.
SP will be given as a single dose consisting of 3 full strength tablets.
Other Names:
|
|
Active Comparator: DP + SP placebo every 4 weeks
|
DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China.
DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
Other Names:
|
|
Active Comparator: SP + DP given every 4 weeks
|
SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda.
SP will be given as a single dose consisting of 3 full strength tablets.
Other Names:
DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China.
DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Risk of Having a Composite Adverse Birth Outcome
Time Frame: Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
Composite adverse birth outcome defined as the occurrence of any of the following:
|
Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
|
Incidence of Serious Adverse Events (SAE) Per Time at Risk
Time Frame: Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
SAEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
|
Incidence of Any Grade 3 or 4 or Serious Adverse Events Per Time at Risk
Time Frame: Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
Grade 3 and 4 AEs or SAEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Time from first dose of study drugs up to 28 days postpartum, an average of 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Spontaneous Abortion
Time Frame: Time of delivery
|
Spontaneous abortion defined as fetal loss at < 28 weeks gestational age
|
Time of delivery
|
|
Incidence of Anemia Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Grade 3-4 AEs Possibly Related to Study Drugs
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs possibly or definitely related to study drug defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Risk of Placental Malaria
Time Frame: At the time of delivery
|
Detection of malaria parasites or pigment by histopathology
|
At the time of delivery
|
|
Incidence of Malaria During Pregnancy
Time Frame: Day study drugs first given until delivery, an average of 6 months
|
Episodes of symptomatic malaria (incidence per person year at risk following initiation of study drugs)
|
Day study drugs first given until delivery, an average of 6 months
|
|
Microscopic Parasitemia During Pregnancy
Time Frame: Day study drugs first given until delivery, an average of 6 months
|
Proportion of routine samples with asexual parasites detected by microscopy
|
Day study drugs first given until delivery, an average of 6 months
|
|
Prevalence of Anemia During Pregnancy
Time Frame: Day study drugs are first given until delivery
|
Proportion of routine hemoglobin measurements < 11 g/dL
|
Day study drugs are first given until delivery
|
|
Stillbirth
Time Frame: Time of delivery
|
Stillbirth defined as infant born deceased at > 28 weeks gestational age
|
Time of delivery
|
|
Low Birth Rate
Time Frame: Time of delivery
|
Low birth weight defined as live birth with birth weight < 2500 gm
|
Time of delivery
|
|
Preterm Delivery
Time Frame: Time of delivery
|
Preterm delivery defined as live birth at < 37 weeks gestational age
|
Time of delivery
|
|
Small-for-gestational Age
Time Frame: Time of delivery
|
Small-for-gestational age defined as live birth with weight-for-gestational age < 10th percentile of reference population
|
Time of delivery
|
|
Neonatal Death
Time Frame: Time of delivery
|
Neonatal death defined as live birth with neonatal death within the first 28 days of life
|
Time of delivery
|
|
Microscopic or Sub-microscopic Parasitemia During Pregnancy
Time Frame: Day study drugs first given until delivery, an average of 6 months
|
Proportion of routine samples with asexual parasites detected by microscopy or qPCR
|
Day study drugs first given until delivery, an average of 6 months
|
|
Prevalence of Severe Anemia During Pregnancy
Time Frame: Day study drugs are first given until delivery, an average of 6 months
|
Proportion of routine hemoglobin measurements < 8 g/dL
|
Day study drugs are first given until delivery, an average of 6 months
|
|
Incidence of Stillbirth Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Congenital Anomaly Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Neutropenia Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Proteinuria Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Thrombocytopenia Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Postpartum Hemorrhage Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Pre-eclampsia Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Preterm Birth <28 Gestational Age Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
|
Incidence of Elevated Temperature Adverse Event Per Time at Risk
Time Frame: Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Grade 3-4 AEs as defined by the July 2017 NIH DAIDS Toxicity Tables
|
Day study drugs are first given until when study participants reach 28 days postpartum or early study termination, an average of 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Grant Dorsey, MD, PhD, University of California, San Francisco
- Principal Investigator: Phil Rosenthal, MD, University of California, San Francisco
- Principal Investigator: Moses Kamya, MBChB, MMed, PhD, Makerere University; Infectious Diseases Research Collaboration
- Study Director: Abel Kakuru, MBChB, PhD, Infectious Diseases Research Collaboration
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Vector Borne Diseases
- Urogenital Diseases
- Genital Diseases
- Mosquito-Borne Diseases
- Genital Diseases, Male
- Male Urogenital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Infections
- Genital Diseases, Female
- Protozoan Infections
- Parasitic Diseases
- Malaria
- Reproductive Tract Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Folic Acid Antagonists
- Anti-Infective Agents, Urinary
- fanasil, pyrimethamine drug combination
Other Study ID Numbers
Other Study ID Numbers
- DPSP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.